Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

Completed · Phase 1

Conditions studied: Bacterial Infections, Obesity

In brief

The purpose of this study is to better understand how clindamycin works in children who fall in the 85th percentile or higher for body mass index (BMI - a ratio of weight to height). The results of the study will help better understand if children in higher BMI ranges process the medication differently and whether dosing should be adjusted in these children.

Key facts

Study ID

NCT01744730

Run by

Phillip Brian Smith

People needed

22

Starts

2013-06-01

Expected to finish

2014-08-01

Last updated by the study team

2016-11-29

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 2 years - < 18 years of age at the time of first dose of study drug
• Suspected or confirmed infection OR receiving IV clindamycin per routine care
• Negative serum pregnancy test (if female and has reached menarche) within 24 hours of first dose of study drug and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy test through the last dose of study drug
• BMI ≥ 85th percentile for age and sex, based on Centers for Disease Control (CDC) recommendations
• Signed informed consent/Health Insurance Portability and Accountability Act (HIPAA) documents by the parent/legal guardian and assent (if applicable)

You may not qualify if…

• The following apply only to those who are NOT already receiving clindamycin per routine care:
• History of hypersensitivity or allergic reaction to clindamycin or lincomycin
• History of C. difficile colitis with previous administration of clindamycin
• Aspartate aminotransferase (AST) > 120 units/L
• Alanine aminotransferase (ALT) > 210 units/L
• Total bilirubin > 3 mg/dL
• Serum creatinine > 2 mg/dL
• Receiving a neuromuscular blocker as part of their therapy
• Previous participation in the study
• Subject is on prohibited medication or herbal product (see Appendix II)
• Subject is receiving extracorporeal life support (ECLS)
• Subject is post-cardiac bypass (within 24 hours)
• Subject on inotropes/pressors
• Any other condition or chronic illness that, in the opinion of the principal investigator, makes participation unadvised or unsafe

Where it is running

• Ann and Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
• Children's Mercy Hospital — Kansas City, Kansas, United States
• University of Louisville — Louisville, Kentucky, United States
• Akron Children's Hospital — Akron, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.